

## Provider Confidence in Counseling Preconception, Pregnant, and Postpartum Patients Regarding COVID-19 Vaccination

Molly R. Siegel, MD<sup>1\*</sup>; Kaitlyn E. James, PhD, MPH<sup>1</sup>; Elana Jaffe, BA, MPH<sup>2</sup>; Michelle M. L'Heureux, MD, FACP<sup>3</sup>; Anjali J. Kaimal, MD, MAS<sup>1</sup>; Ilona T. Goldfarb, MD<sup>1</sup>

<sup>1</sup>Department of Obstetrics and Gynecology, Massachusetts General Hospital, Boston, MA

<sup>2</sup> School of Medicine, University of North Carolina at Chapel Hill

<sup>3</sup> Massachusetts General Hospital, Boston, MA

\*Corresponding Author: Molly R. Siegel, MD, Department of Obstetrics and Gynecology, Massachusetts General Hospital. Email: [mrsiegel@partners.org](mailto:mrsiegel@partners.org)

1 Abstract

2 *Objective:* To assess knowledge and confidence in COVID-19 vaccine counseling among  
3 practitioners who provide care to pregnant persons and to describe factors associated with  
4 confidence in counseling.

5

6 *Study Design:* A web-based anonymous survey was distributed via email to a cross-sectional  
7 convenience sample of OB/GYN, Primary Care, and Internal Medicine faculty at three hospitals  
8 in a single healthcare network in Massachusetts. Individual demographics and institution-specific  
9 variables were included in the survey along with questions assessing both attitudes toward  
10 COVID-19 illness in pregnancy as well as confidence in counseling regarding the use of the  
11 vaccine for pregnant patients.

12

13 *Results:* Almost all providers (151, 98.1%) reported already receiving or being scheduled to  
14 receive a COVID-19 vaccine, and a majority of providers (111, 72.1%) reported that they believe  
15 the benefits of the mRNA COVID-19 vaccine in pregnancy outweigh the risks. Forty-one  
16 (26.6%) reported feeling very confident in counseling patients who primarily speak English  
17 about the evidence for mRNA vaccination in pregnancy, and 36 (23%) reported feeling very  
18 confident in counseling patients who are not primarily English-speaking. Forty-three providers  
19 (28.1%) expressed strong confidence in their comfort talking to individuals with vaccine  
20 hesitancy based on historic and continued racism and systemic injustices. The sources that  
21 survey respondents most commonly used to find information regarding COVID-19 vaccination  
22 in pregnancy were the CDC (112, 74.2%), hospital-specific resources (94, 62.3%) and ACOG  
23 (82, 54.3%).

24

25 *Conclusion:* While providers reported high personal uptake of COVID-19 vaccination and felt  
26 that the benefits of vaccination outweigh the risks in pregnancy, less than one-third felt very  
27 confident in counseling pregnant patients about available evidence for mRNA vaccine safety in  
28 pregnancy. Ensuring that providers feel comfortable bridging the gap between their belief that  
29 the vaccine is beneficial for pregnant patients and their comfort with holding conversations with  
30 patients regarding vaccination is paramount in order to ensure equitable access to vaccines for  
31 pregnant patients.

32

33

34 Keywords

35 Pregnancy, vaccine hesitancy, COVID-19, prenatal, postpartum, preconception, vaccine  
36 counseling

37

38 Background:

39 Pregnant people were considered a priority population for COVID-19 vaccination in a majority  
40 of states.<sup>1</sup> Their prioritization in vaccine eligibility stems from growing evidence that pregnant  
41 individuals are at increased risk of complications from COVID-19 infection, including  
42 hospitalization, intensive care unit (ICU) admission, and need for invasive ventilation, and  
43 death.<sup>2</sup> As with other groups at increased risk for complications due to COVID-19, they stand to  
44 benefit from vaccination. However, pregnant and lactating persons were not included in early  
45 trials of the vaccine, and as such, there are fewer data to inform use in these groups. As a result,  
46 patients face potentially challenging decisions surrounding vaccination in pregnancy and  
47 lactation. Together with their providers, pregnant individuals must consider the high level of  
48 protection afforded by the vaccine together with the limited evidence around vaccine safety in  
49 pregnancy, the established increased risk of morbidity and mortality associated with contracting  
50 the virus while pregnant, and their individual level of risk due to occupation, underlying medical  
51 conditions, or other factors.

52

53 Despite lack of data from randomized controlled trials, the Centers for Disease Control (CDC)  
54 and the Advisory Committee on Immunization Practices (ACIP), along with the American  
55 College of Obstetricians and Gynecologists (ACOG) and the Society for Maternal Fetal  
56 Medicine (SMFM), all support the provision of these vaccines to pregnant and breastfeeding  
57 individuals. While consultation is not required, these organizations encourage patients to seek  
58 counsel from their healthcare providers in deciding whether or not to receive the vaccine and  
59 recommend that healthcare providers engage in shared decision making with patients.<sup>3,4</sup> As  
60 pregnant and lactating individuals consider whether they should get the COVID-19 vaccine, it is

61 paramount that providers feel knowledgeable and comfortable counseling patients. However,  
62 healthcare provider knowledge and confidence surrounding COVID-19 vaccine counseling in  
63 pregnancy and lactation has not been assessed.

64

65 The purpose of this survey study is to assess knowledge and confidence in COVID-19 vaccine  
66 counseling among practitioners who provide care to pregnant patients and to describe factors  
67 associated with confidence with counseling. It is our goal that understanding these factors will  
68 help to identify resources needed to improve healthcare provider confidence and improve  
69 counseling around shared decision making for vaccination for pregnant individuals.

70

#### 71 Methods:

##### 72 Participants

73 The survey participants were drawn from a cross-sectional convenience sample of OB/GYN,  
74 Primary Care, and Internal Medicine faculty at three hospitals (one urban academic medical  
75 center with 3800 deliveries per year, one suburban community hospital with 4500 deliveries per  
76 year, and one rural community hospital with 600 deliveries per year) in a single healthcare  
77 network in Massachusetts. Participants were asked via email to participate in an online  
78 anonymous survey in February 2021. The survey email was sent to MD, DO, CNM, and NP  
79 faculty by their division administrators with two follow-up reminder emails. Consent to  
80 participate in the survey was implied by voluntary participation in the anonymous survey.

81

##### 82 Survey

83 The web-based anonymous survey was designed to accommodate quantitative analysis of  
84 questions with nominal, ordinal, and interval level measurement and was reviewed by 3 experts  
85 in qualitative research methods and survey design. Individual demographics and institution-  
86 specific variables were included in the survey along with questions assessing both attitudes  
87 toward COVID-19 illness in pregnancy as well as confidence in counseling regarding the use of  
88 the vaccine for preconception, pregnant, and lactating patients.

89

90 The study and survey instrument were approved by the Partners Healthcare IRB (IRB #  
91 2021P000088).

92

### 93 Data Analysis

94 Data were analyzed using Stata/IC 16.1. For quantitative variables, descriptive statistics are  
95 presented to illustrate the distribution of the respondent demographics and survey responses. To  
96 determine predictors of confidence in counseling, multivariable logistic regression models were  
97 used. Separate models were generated to determine predictors of confidence and agreement (as  
98 defined as responding “very confident” or “strongly agree”) in counseling English-speaking and  
99 non-English speaking patients about mRNA COVID-19 vaccine safety, and in counseling  
100 patients with vaccine hesitancy stemming from historic and ongoing systemic racism and a belief  
101 that vaccines in general are harmful. Covariates for the multivariable models were chosen a  
102 priori; all models included provider specialty, frequency of being asked advice about COVID-19  
103 vaccine, experience managing patients with COVID-19, and a personal belief that the COVID-19  
104 vaccine benefits outweighed the risks. Confidence in counseling non-English speaking patients  
105 also included whether the respondent spoke more than one language; provider race was

106 additionally included in the model for counseling patients with vaccine hesitancy based on  
107 historic and continued racism.  $P < 0.05$  was considered statistically significant.

108

## 109 Results

### 110 *Provider demographics*

111 There were 154 providers who responded to the survey. Demographic characteristics are shown  
112 in **Table 1**. Almost half of providers worked in obstetrics; approximately 70% of participants  
113 were medical doctors and a third were advanced practice practitioners. Most respondents  
114 identified as White/Caucasian and reported English as their primary language, while almost half  
115 of respondents reported speaking another language in addition to English.

116 The majority of participants (140, 91.5%) reported that their institution was offering the COVID-  
117 19 vaccine to eligible pregnant individuals, and 137 (89.5%) reported that their institution was  
118 offering the vaccine to postpartum individuals. Most providers (126, 81.8%) reported that since  
119 December 2020, they had been asked to offer advice surrounding COVID-19 vaccination in  
120 pregnancy and postpartum to patients at least once per week, and slightly less than half (67,  
121 43.5%) % participated in this counseling 2-10 times per week. Most providers (124, 80.5%) had  
122 cared for patients with COVID-19 in the outpatient setting, though fewer (73, 47.4%) had cared  
123 for pregnant outpatients with COVID-19 . Similarly, while just over half of providers had  
124 managed patients with COVID-19 in an inpatient setting, fewer (58, 37.7%) reported managing  
125 pregnant patients with COVID-19 in the inpatient setting.

126 Survey respondents had high COVID-19 vaccine utilization for themselves. Almost all providers  
127 (151, 98.1%) reported already receiving or being scheduled to receive a COVID-19 vaccine.

128 Respondents also reported that they frequently recommend other vaccines in pregnancy. Almost

129 all providers (142, 92.2%) reported that they always recommend the flu vaccine for pregnant  
130 individuals during flu season, and the majority (119, 77.3%) reported that they recommend the  
131 Tdap vaccine for pregnant individuals during every pregnancy.

132 *Provider beliefs about risk-benefit ratio*

133 Beliefs about the efficacy and safety of mRNA COVID-19 vaccines are shown in **Figure 1**. A  
134 majority of providers (111, 72.1%) reported the opinion that the benefits of the mRNA COVID-  
135 19 vaccine in pregnancy outweigh the risks. Several (21, 13.6%) were unsure about the risk-  
136 benefit ratio and agreed that additional data and more directive guidance from governing  
137 societies would be needed to guide a definitive opinion. A similar number (21, 13.6%) reported  
138 that the benefits outweighed the risks only in specific circumstances, including where patients  
139 had underlying co-morbidities, increased occupational exposure, lived in congregate housing, or  
140 were experiencing incarceration. Only 1 provider (0.6%) stated the belief that the benefits of the  
141 COVID-19 vaccine did not outweigh the risks of vaccination in pregnancy, citing unknown fetal  
142 safety. The most common rationales supporting the belief that the benefits of COVID-19  
143 vaccines outweighed any risk were that pregnant individuals face increased risk of severe disease  
144 from COVID-19 infection, the likely low theoretical risk of mRNA COVID-19 vaccines in  
145 pregnancy, and because vaccine efficacy is likely to be similar between pregnant and non-  
146 pregnant individuals. The majority of providers (141, 92.2%) agreed that the benefits of  
147 COVID-19 vaccination during breastfeeding outweighed any risks, with 11 (7.2%) unsure and  
148 none in disagreement. Similarly, the majority of providers (133, 86.9%) agreed that the benefits  
149 of COVID-19 vaccines outweigh the risks for individuals planning pregnancy within three  
150 months.



151 Provider confidence in counseling patients who primarily speak English and those who do not  
152 primarily speak English about the vaccine is shown in **Figure 2**. When asked if that they could  
153 answer questions about the available evidence for mRNA COVID-19 vaccine safety in pregnant  
154 individuals, 41 (26.6%) reported feeling very confident in counseling patients who primarily  
155 speak English, and 36 (23%) reported feeling very confident in counseling patients who are not  
156 primarily English-speaking. There were no differences in confidence in counseling English-  
157 speaking patients about vaccine safety in pregnancy by provider type, but primary care and  
158 internal medicine providers were more likely to state that they feel very confident answering  
159 questions from non-English-speaking patients about the available evidence of mRNA COVID-19  
160 vaccine safety in pregnant individuals (aOR 4.14, 95% CI 1.25-13.7).

161

### 162 *Provider comfort with counseling patients with vaccine hesitancy*

163 Provider comfort with counseling patients with vaccine hesitancy is shown in **Figure 3**.  
164 Most providers expressed some confidence in counseling individuals with vaccine hesitancy  
165 based on historic and continued racism and systemic injustices (111, 72.5%); however, only 43  
166 providers (28.1%) reported feeling strongly confident with this counseling. Similarly, only 50  
167 providers described the highest level of comfort counseling individuals with vaccine hesitancy  
168 grounded in general beliefs that vaccines are harmful. Those who believe the benefits of the  
169 vaccine outweigh the risks were also more likely to strongly agree with the statement that they  
170 feel comfortable talking to individuals whose vaccine hesitancy was based on historic and  
171 continued racism and systemic injustice (aOR 4.38, 95% CI 1.47-13.0) and to those whose  
172 hesitancy is based on beliefs that vaccines in general are harmful (aOR 5.56, 95% CI 1.98-15.6).

173 The sources that survey respondents most commonly used to find information regarding COVID-  
174 19 vaccination in pregnancy were the CDC (112 respondents, 74.2%), Hospital-specific  
175 resources (94 respondents, 62.3%) and ACOG (82 respondents, 54.3%). When asked to select  
176 the tool that would be most useful in helping them feel more confident in counseling pregnant  
177 patients regarding COVID-19 vaccination, 32 participants (20.9%) stated “A presentation from  
178 an expert in the field of obstetrics and gynecology”, 22 participants (14.4%) selected “A decision  
179 tool to use with my patients”, and 16 participants (10.5%) selected “A handout geared towards  
180 patients.”

## 181 Discussion

182 Vaccination against COVID-19 is considered the cornerstone of pandemic management. CDC  
183 recommendations are permissive about COVID-19 vaccine use in pregnancy, though there is no  
184 explicit recommendation that pregnant people *should* receive the vaccine as there is for the  
185 general adult population. Guidance from the CDC and ACOG cite provider consultation as  
186 important (though not required) for decision-making about COVID-19 vaccination in pregnancy.  
187 Due to the absence of pregnancy specific vaccine evidence, and a lack of a clear directive to  
188 vaccinate all pregnant individuals, provider counseling will play a critical role in COVID-19  
189 vaccine acceptance among pregnant people.

190

191 Provider understanding of and feelings towards vaccination have previously been shown to be  
192 key factors in their likelihood of recommending vaccination.<sup>5-7</sup> Provider recommendation is also  
193 a significant factor for patient vaccine uptake.<sup>8-11</sup> Despite the CDC’s offer for patients to discuss  
194 their decision with a healthcare provider and the pivotal role of healthcare providers in

195 influencing vaccine uptake, little is known about how ready and confident providers feel to  
196 engage in this shared decision-making counseling.

197

198 In our study, respondents reported a high level of COVID-19 vaccine acceptance for themselves.

199 Vaccinated healthcare providers have previously been shown to be more likely to recommend

200 vaccines to their patients.<sup>12</sup> The high levels of vaccine acceptance in this group suggests that it is

201 a population that would be eager and amenable to counseling patients towards vaccination.

202 Furthermore, most providers believe that the benefits of COVID-19 vaccination in pregnancy

203 outweigh the risks, citing that pregnant individuals face increased risk of severe disease from

204 COVID-19 infection and that there is low theoretical risk of harm from mRNA vaccine in

205 pregnancy.

206

207 However, we identified a discrepancy between provider acceptance of vaccination as beneficial

208 for pregnant individuals and their own comfort in engaging in conversations regarding the

209 vaccine in pregnancy. Although 84.1% believed the benefits outweighed the risks in some or all

210 circumstances, fewer expressed some confidence in answering questions about COVID-19

211 vaccine safety in pregnancy. Importantly, less than one-third of providers in our survey felt very

212 confident in counseling pregnant patients about available evidence for mRNA vaccine safety in

213 pregnancy, despite that nearly half had over 20 years of clinical experience. This disconnect

214 between belief in efficacy and confidence in counseling is of particular concern and may impact

215 the vaccination rates of patients

216

217 Overall, providers reported that they most trust information from their institution, the CDC, and  
218 ACOG regarding vaccination in pregnancy. Both ACOG and the CDC have developed tools for  
219 providers to guide conversations with patients around vaccination.<sup>13-15</sup> These institutions can  
220 continue to provide guidance surrounding vaccine safety and efficacy as well as develop new  
221 counseling strategies for providers to improve comfort with counseling. They can engage  
222 community partners to involve those with vaccine hesitancy in vaccination campaigns and  
223 provider interactions. Based on our survey responses, these organizations may consider increased  
224 dissemination of information about ongoing presentations from experts in the field of obstetrics  
225 and gynecology and decision tools that providers may use with patients to improve confidence  
226 with vaccine counseling.

227

228 Although participants in our study reported moderate rates of confidence in counseling patients  
229 with vaccine hesitancy, less than one-third of participants strongly agreed that they felt confident  
230 in counseling patients with vaccine hesitancy based on historic and ongoing racism and systemic  
231 injustice. Provider lack of comfort in counseling those with vaccine hesitancy may further  
232 perpetuate racial inequities that have been highlighted by the pandemic, with disparities in  
233 vaccination rates as well as COVID-19 infection, hospitalization, and death rates.<sup>16,17</sup> As others  
234 have pointed out, the concept of “vaccine hesitancy” puts the onus of disparities in vaccination  
235 rates on the patient rather than the provider and the healthcare systems that perpetuate mistrust  
236 and disparity.<sup>18</sup> Our findings suggest a need for broader strategies for educating providers about  
237 the impact of systemic racism on both patient uncertainty as well as provider confidence in these  
238 encounters to improve confidence in vaccine counseling and ensuring equity in access. One long-  
239 term strategy proposed by Ojikutu et al is to longitudinally partner with and invest in

240 communities of color from the initiation of vaccine research to community education,  
241 community-based organizations, and leadership in order to build trust and provide equitable  
242 inclusion in vaccination trials and implementation.<sup>19</sup>

243

244 Strengths of this study include that it represents a cross-sectional and inter-professional sample  
245 of specialties, practice settings, and provider types to surface the lived experiences of providers  
246 engaging in vaccine counseling for a vulnerable population during a pandemic. Limitations  
247 include that this study was performed in the early phases of vaccination; as more data  
248 surrounding vaccination in pregnancy become available, providers may have shifting comfort  
249 with this counseling. Furthermore, participants who opted to complete the survey may have a  
250 different level of confidence with this counseling compared to the general provider population.  
251 In addition, this sample represents a group of predominantly non-Hispanic White clinicians with  
252 high baseline vaccine trust, as nearly all providers received the vaccine themselves, and most  
253 stated that they always recommend the influenza and Tdap vaccines to pregnant patients. Nearly  
254 half spoke a second language, which may increase their confidence in counseling non-English  
255 speaking patients. As such, the confidence of this group may overrepresent the confidence of all  
256 clinicians who engage in vaccine counseling with pregnant patients. Finally, this study was  
257 conducted prior to the authorization of the vaccine developed by Janssen, which does not use an  
258 mRNA platform.

259

## 260 CONCLUSION

261 As pregnant patients become increasingly eligible for COVID-19 vaccination nationwide,  
262 provider-initiated counseling regarding the safety and efficacy of vaccination will necessarily

263 become a common occurrence in general medicine , primary care, and obstetric care. While the  
264 lack of inclusion of pregnant participants in the initial clinical trials of vaccination makes these  
265 discussions challenging, it also may increase their influence on vaccine uptake. Ensuring that  
266 providers feel comfortable bridging the gap between their belief that the vaccine is beneficial for  
267 pregnant patients and their comfort with holding conversations with patients regarding  
268 vaccination is paramount in order to ensure equitable access to vaccines for pregnant patients.

269

270 Table 1: Survey Respondents

	N=154
<u>Age (mean, SD)</u>	46.2 (11.5)
<u>Race</u>	
Black/African American	6 (3.9%)
White	131 (85.1%)
Asian	11 (7.1%)
Other	3 (1.9%)
Not reported	3 (1.9%)
<u>Ethnicity</u>	
Hispanic/Latinx	5 (3.2%)
Not Hispanic/Latinx	142 (92.2%)
Not reported	7 (4.5%)

<u>Language</u>	
English as primary language	153 (99.4%)
At least one other language	76 (49.4 %)
<u>Gender</u>	
Female	124 (80.5%)
Male	24 (15.6%)
Non-binary	1 (0.6%)
Prefer not to answer	3 (1.9%)
Not reported	2 (1.3%)
<u>Years in healthcare</u>	
< 5 years	7 (4.5%)
5-10 years	37 (24.0%)
10-20 years	38 (24.7%)
>20 years	70 (45.5%)
Not reported	2 (1.3%)
<u>Specialty</u>	
OB-Only	13 (8.4%)
OB/GYN	62 (40.3%)
Primary Care	46 (29.9%)

Internal Medicine	21 (13.6%)
Other	10 (6.5%)
Not reported	2 (1.3%)
<u>Practitioner type</u>	
MD/DO	109 (70.8%)
CNM	26 (16.9%)
NP	19 (12.3%)
<u>Practice Setting</u>	
Private practice, community-hospital	10 (6.5%)
Group practice, community hospital	48 (31.2%)
Private practice, academic hospital	3 (1.9%)
Group practice, academic hospital	86 (55.8%)
Other	7 (4.5%)

271


272

273



274

275 Figure 1: Attitudes towards mRNA COVID-19 Vaccine



276

277


278

279 **Figure 2: Counseling Confidence in Primarily English Speaking and Primarily Non-English-**

280 **Speaking Patients**


281

282 **When Counseling Patients who are Primarily English Speaking**



283

284 **When Counseling Patients who are Primarily Non-English Speaking**




285

286


287

288 **Figure 3: Provider Comfort with Counseling Patients with Vaccine Hesitancy**



289

290



291

292

293

294

295

296

297 **References**

- 298 1. Crane MA, Jaffe E, Beigi RH, et al. Prioritization of pregnant individuals in state plans  
299 for coronavirus disease 2019 vaccination. *Am J Obstet Gynecol* 2021. DOI:  
300 10.1016/j.ajog.2021.03.015.
- 301 2. Yap M, Debenham L, Kew T, et al. Clinical manifestations, prevalence, risk factors,  
302 outcomes, transmission, diagnosis and treatment of COVID-19 in pregnancy and  
303 postpartum: a living systematic review protocol. *BMJ Open* 2020;10(12):e041868. DOI:  
304 10.1136/bmjopen-2020-041868.
- 305 3. Advisories ACoP. Vaccinating Pregnant and Lactating Patients Against COVID-19.  
306 *Obstetrics and Gynecology* 2020 ([https://www.acog.org/clinical/clinical-  
307 guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-  
308 against-covid-  
309 19#:~:text=ACOG%20recommends%20that%20COVID%2D19,similar%20to%20non%  
310 2Dlactating%20individuals.](https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/vaccinating-pregnant-and-lactating-patients-against-covid-19#:~:text=ACOG%20recommends%20that%20COVID%2D19,similar%20to%20non%2Dlactating%20individuals.)).
- 311 4. SMFM Aa. ACOG and SMFM Joint Statement on WHO Recommendations Regarding  
312 COVID-19 Vaccines and Pregnant Individuals.  
313 ([https://s3.amazonaws.com/cdn.smfm.org/media/2726/WHO\\_Response.pdf](https://s3.amazonaws.com/cdn.smfm.org/media/2726/WHO_Response.pdf)).
- 314 5. Dube E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J. Vaccine hesitancy: an  
315 overview. *Hum Vaccin Immunother* 2013;9(8):1763-73. DOI: 10.4161/hv.24657.
- 316 6. Shavell VI, Moniz MH, Gonik B, Beigi RH. Influenza immunization in pregnancy:  
317 overcoming patient and health care provider barriers. *Am J Obstet Gynecol* 2012;207(3  
318 Suppl):S67-74. DOI: 10.1016/j.ajog.2012.06.077.

- 319 7. Silverman NS, Greif A. Influenza vaccination during pregnancy. Patients' and physicians'  
320 attitudes. *J Reprod Med* 2001;46(11):989-94.  
321 (<https://www.ncbi.nlm.nih.gov/pubmed/11762156>).
- 322 8. Doherty M, Schmidt-Ott R, Santos JI, et al. Vaccination of special populations:  
323 Protecting the vulnerable. *Vaccine* 2016;34(52):6681-6690. DOI:  
324 10.1016/j.vaccine.2016.11.015.
- 325 9. Wilson RJ, Paterson P, Jarrett C, Larson HJ. Understanding factors influencing  
326 vaccination acceptance during pregnancy globally: A literature review. *Vaccine*  
327 2015;33(47):6420-9. DOI: 10.1016/j.vaccine.2015.08.046.
- 328 10. Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in  
329 the United States: How many people would get vaccinated? *Vaccine* 2020;38(42):6500-  
330 6507. DOI: 10.1016/j.vaccine.2020.08.043.
- 331 11. Ellingson MK, Dudley MZ, Limaye RJ, Salmon DA, O'Leary ST, Omer SB. Enhancing  
332 uptake of influenza maternal vaccine. *Expert Rev Vaccines* 2019;18(2):191-204. DOI:  
333 10.1080/14760584.2019.1562907.
- 334 12. Paterson P, Meurice F, Stanberry LR, Glismann S, Rosenthal SL, Larson HJ. Vaccine  
335 hesitancy and healthcare providers. *Vaccine* 2016;34(52):6700-6706. DOI:  
336 10.1016/j.vaccine.2016.10.042.
- 337 13. Gynecologists TACoOa. COVID-19 Vaccines and Pregnancy: Conversation Guide for  
338 Clinicians 2021:[https://www.acog.org/covid-19/covid-19-vaccines-and-pregnancy-  
339 conversation-guide-for-clinicians](https://www.acog.org/covid-19/covid-19-vaccines-and-pregnancy-conversation-guide-for-clinicians).

- 340 14. Gynecologists TACoOa. COVID-19 Vaccines: Tools for Your Practice and Your Patients  
341 2021:[https://www.acog.org/covid-19/covid-19-vaccines-tools-for-your-practice-and-  
your-patients](https://www.acog.org/covid-19/covid-19-vaccines-tools-for-your-practice-and-<br/>342 your-patients).
- 343 15. Control CfD. Answering Patients' Questions About COVID-19 Vaccine and Vaccination.  
344 cdc.gov2021:<https://www.cdc.gov/vaccines/covid-19/hcp/answering-questions.html>.
- 345 16. Laurencin CT. Addressing Justified Vaccine Hesitancy in the Black Community. J Racial  
346 Ethn Health Disparities 2021. DOI: 10.1007/s40615-021-01025-4.
- 347 17. Prevention CfDCa. Risk for COVID-19 Infection, Hospitalization, and Death by  
348 Race/Ethnicity.
- 349 18. Corbie-Smith G. Vaccine Hesitancy is a Scapegoat for Structural Racism. Jama Health  
350 Forum 2021 (<https://jamanetwork.com/channels/health-forum/fullarticle/2778073>).
- 351 19. Ojikutu BO, Stephenson KE, Mayer KH, Emmons KM. Building Trust in COVID-19  
352 Vaccines and Beyond Through Authentic Community Investment. Am J Public Health  
353 2021;111(3):366-368. DOI: 10.2105/AJPH.2020.306087.

354

355

356